Clinical features and hematologic responses
. | Low-Dose Group . | High-Dose Group . | ||||
---|---|---|---|---|---|---|
TFPI . | Placebo . | P . | TFPI . | Placebo . | P . | |
Peak temperature (°C) | 38.6 ± 0.2 | 38.8 ± 0.2 | NS | 38.3 ± 0.2 | 38.2 ± 0.2 | NS |
Time to temperature peak (h) | 3.6 ± 0.2 | 3.6 ± 0.2 | NS | 3.9 ± 0.2 | 3.9 ± 0.4 | NS |
Heart rate (peak, bpm) | 107 ± 3.9 | 110 ± 3.0 | NS | 102 ± 6.4 | 99 ± 3.0 | NS |
Systolic blood pressure (nadir, mm Hg) | 103 ± 5.1 | 104 ± 2.0 | NS | 105 ± 2.7 | 106 ± 2.9 | NS |
White blood count (×109/L) | ||||||
Nadir | 2.5 ± 0.1 | 2.1 ± 0.2 | NS | 2.0 ± 0.2 | 1.9 ± 0.1 | NS |
Peak | 14.1 ± 0.7 | 14.6 ± 1.4 | NS | 13.9 ± 0.8 | 13.1 ± 1.3 | NS |
. | Low-Dose Group . | High-Dose Group . | ||||
---|---|---|---|---|---|---|
TFPI . | Placebo . | P . | TFPI . | Placebo . | P . | |
Peak temperature (°C) | 38.6 ± 0.2 | 38.8 ± 0.2 | NS | 38.3 ± 0.2 | 38.2 ± 0.2 | NS |
Time to temperature peak (h) | 3.6 ± 0.2 | 3.6 ± 0.2 | NS | 3.9 ± 0.2 | 3.9 ± 0.4 | NS |
Heart rate (peak, bpm) | 107 ± 3.9 | 110 ± 3.0 | NS | 102 ± 6.4 | 99 ± 3.0 | NS |
Systolic blood pressure (nadir, mm Hg) | 103 ± 5.1 | 104 ± 2.0 | NS | 105 ± 2.7 | 106 ± 2.9 | NS |
White blood count (×109/L) | ||||||
Nadir | 2.5 ± 0.1 | 2.1 ± 0.2 | NS | 2.0 ± 0.2 | 1.9 ± 0.1 | NS |
Peak | 14.1 ± 0.7 | 14.6 ± 1.4 | NS | 13.9 ± 0.8 | 13.1 ± 1.3 | NS |